Legal & General Group Plc Has $16.01 Million Stock Holdings in Guardant Health, Inc. $GH

Legal & General Group Plc increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 3.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 156,779 shares of the company’s stock after purchasing an additional 5,174 shares during the quarter. Legal & General Group Plc’s holdings in Guardant Health were worth $16,013,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new stake in Guardant Health during the fourth quarter worth about $27,000. Chesapeake Asset Management LLC acquired a new stake in Guardant Health during the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health during the fourth quarter valued at approximately $35,000. Finally, First Pacific Financial acquired a new stake in Guardant Health during the fourth quarter valued at approximately $43,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Trading Down 0.4%

NASDAQ:GH opened at $129.14 on Tuesday. Guardant Health, Inc. has a 1 year low of $39.69 and a 1 year high of $133.97. The firm has a 50 day moving average of $95.88 and a 200-day moving average of $100.18. The stock has a market capitalization of $17.12 billion, a P/E ratio of -38.09 and a beta of 1.48.

Insider Buying and Selling

In other news, CEO Amirali Talasaz sold 210,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the transaction, the chief executive officer owned 1,886,504 shares in the company, valued at approximately $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Terilyn J. Monroe sold 3,832 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the transaction, the insider owned 20,990 shares of the company’s stock, valued at $1,945,353.20. This trade represents a 15.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 332,244 shares of company stock valued at $36,156,026 in the last ninety days. 5.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GH has been the topic of a number of recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Piper Sandler set a $127.00 price objective on Guardant Health in a report on Thursday, May 21st. Evercore set a $110.00 price objective on Guardant Health in a report on Friday, February 20th. Finally, BTIG Research set a $160.00 price objective on Guardant Health and gave the company a “buy” rating in a report on Wednesday, May 27th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.79.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.